Skip to main content
LLM 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Session III: AML and MDS

Debate: All Non-FLT3 Mutated AML Patients Above Age 60 with ELN Intermediate or Adverse Risk Should Be Treated with Azacitidine and Venetoclax - NO

Wednesday, October 18, 2023
3:00 PM - 3:15 PM ET
Location: Metropolitan East

    Debate Speaker(s)

  • Tapan Kadia, MD

    MD Anderson Cancer Center
    Bellaire, Texas, United States